Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review-Reference-Cited by-同舟云学术

Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review

Published:2023-10-12 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Sheikh Ibrahimkhalil M,Hassan Omar A,Adam Siad Mohammed,Ali Abdirazak I,Ogedegbe Oboseh J,Tabowei Godfrey,Barbarawi Ahmed,Yussuf Feisal M,Nor Mohammed A

Publisher

Springer Science and Business Media LLC

Subject

Aerospace Engineering

Reference35 articles.

1. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug;Nesti L;Cardiovasc Diabetol,2021

2. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta;Mizoguchi M;JACC Cardiovasc Imaging,2011

3. Pioglitazone after ischemic stroke or transient ischemic attack;Kernan WN;N Engl J Med,2016

4. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial;Vaccaro O;Lancet Diabetes Endocrinol,2017

5. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials;Lago RM;Lancet,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells;Biomedicines;2023-11-14